Invesco
MLYS icon

Invesco’s Mineralys Therapeutics MLYS Stock Holding History

Invesco’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.4M Buy
1,091,180
+1,048,869
+2,479% +$28.8M ﹤0.01% 1318
2026
Q1 		$1.15M Buy
42,311
+13,170
+45% +$386K ﹤0.01% 2803
2025
Q4 		$1.06M Sell
29,141
-158,845
-84% -$6.37M ﹤0.01% 2885
2025
Q3 		$7.13M Buy
187,986
+162,243
+630% +$3.51M ﹤0.01% 2039
2025
Q2 		$348K Sell
25,743
-282,567
-92% -$4.09M ﹤0.01% 3312
2025
Q1 		$4.9M Buy
+308,310
New +$3.55M ﹤0.01% 2161

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco's MLYS Position: Q2 2026 in Review

Invesco increased its Mineralys Therapeutics (MLYS) stake by 2,479% in Q2 2026, buying an estimated $28.8M and bringing the position to 1,091,180 shares worth $29.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Invesco first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Invesco held 1,091,180 shares of Mineralys Therapeutics worth $29.4M as of Q2 2026.
  • Invesco bought 1,048,869 Mineralys Therapeutics shares in Q2 2026, an estimated $28.8M.
  • Mineralys Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1318 holding.
  • Invesco first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.